COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).
Bikdeli, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 2950–2973 (2020).
Connors, J. M. & Levy, J. H. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 18, 1559–1561 (2020).
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452 (2020).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).
Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus.J. Virol. 94, e00127-20 (2020).
Madjid, M., Safavi-Naeini, P., Solomon, S. D. & Vardeny, O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1286 (2020).
Driggin, E. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 75, 2352–2371 (2020).
Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259–260 (2020).
Han, Y. et al. CSC expert consensus on principles of clinical management of patients with severe emergent cardiovascular diseases during the COVID-19 epidemic. Circulation 141, e810–e816 (2020).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA https://doi.org/10.1001/jama.2020.1585 (2020).
Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA https://doi.org/10.1001/jama.2020.2648 (2020).
Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846–848 (2020).
Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.0950 (2020).
Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1017 (2020).
Shi, S. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur. Heart J. 41, 2070–2079 (2020).
Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. & Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607–1608 (2020).
Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499–1504 (2020).
Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335 (2020).
Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192 (2019).
Du, L. et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009).
Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).
Bar-On, Y. M., Flamholz, A., Phillips, R. & Milo, R. SARS-CoV-2 (COVID-19) by the numbers. Elife https://doi.org/10.7554/eLife.57309 (2020).
Masson, P. et al. ViralZone: recent updates to the virus knowledge resource. Nucleic Acids Res. 41, D579–D583 (2013).
Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing COVID-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969–1973 (2020).
Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040 (2020).
Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020).
Ho, T. Y., Wu, S. L., Chen, J. C., Li, C. C. & Hsiang, C. Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir. Res. 74, 92–101 (2007).
Robson, B. COVID-19 coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed Achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput. Biol. Med. 121, 103749–103749 (2020).
Perlman, S. & Masters, P. S. in Fields Virology: Emerging Viruses (eds Howley, P. M & knipe, D. M.) 410–448 (Lippincott Williams & Wilkins, 2020).
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA https://doi.org/10.1001/jama.2020.6019 (2020).
Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149–150 (2020).
Li, S. S. et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation 108, 1798–1803 (2003).
Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Wkly 2, 113–122 (2020).
Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA https://doi.org/10.1001/jama.2020.5394 (2020).
Goyal, P. et al. Clinical characteristics of COVID-19 in New York City. N. Engl. J. Med. 382, 2372–2374 (2020).
Arentz, M. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA https://doi.org/10.1001/jama.2020.4326 (2020).
Bhatraju, P. K. et al. COVID-19 in critically ill patients in the Seattle region — case series. N. Engl. J. Med. 382, 2012–2022 (2020).
Onder, G., Rezza, G. & Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA https://doi.org/10.1001/jama.2020.4683 (2020).
Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA https://doi.org/10.1001/jama.2020.6775 (2020).
Stefanini, G. G. et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation 141, 2113-2116 (2020).
Deng, Q. et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int. J. Cardiol. 311, 116–121 (2020).
Wang, D. et al. Chinese Society of Cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci. China Life Sci. 62, 187–202 (2019).
Inciardi, R. M. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1096 (2020).
Hu, H., Ma, F., Wei, X. & Fang, Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehaa190 (2020).
Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420–422 (2020).
Tavazzi, G. et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 22, 911–915 (2020).
Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. https://doi.org/10.7326/M20-2003 (2020).
Schaller, T. et al. Postmortem examination of patients with COVID-19. JAMA https://doi.org/10.1001/jama.2020.8907 (2020).
Jiang, F. et al. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat. Rev. Cardiol. 11, 413–426 (2014).
Oudit, G. Y. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest. 39, 618–625 (2009).
Kwong, J. C. et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N. Engl. J. Med. 378, 345–353 (2018).
Madjid, M. et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur. Heart J. 28, 1205–1210 (2007).
Chong, P. Y. et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch. Pathol. Lab. Med. 128, 195–204 (2004).
Bangalore, S. et al. ST-segment elevation in patients with COVID-19 – a case series. N. Engl. J. Med. 382, 2478-2480 (2020).
Libby, P., Tabas, I., Fredman, G. & Fisher, E. A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867–1879 (2014).
Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 114, 1852–1866 (2014).
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418 (2020).
Garcia, S. et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J. Am. Coll. Cardiol. 75, 2871–2872 (2020).
De Filippo, O. et al. Reduced rate of hospital admissions for ACS during COVID-19 outbreak in Northern Italy. N. Engl. J. Med. 383, 88–89 (2020).
Rodríguez-Leor, O. et al. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. Rec. Interventional Cardiol. Engl. Ed. https://doi.org/10.24875/recice.M20000123 (2020).
De Rosa, S. et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur. Heart J. 41, 2083–2088 (2020).
Baldi, E. et al. Out-of-hospital cardiac arrest during the COVID-19 outbreak in Italy. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2010418 (2020).
Pessoa-Amorim, G. et al. Admission of patients with STEMI since the outbreak of the COVID-19 pandemic. A survey by the European Society of Cardiology. Eur. Heart J. Qual. Care Clin. Outcomes https://doi.org/10.1093/ehjqcco/qcaa046 (2020).
Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).
Mehra, M. R. & Ruschitzka, F. COVID-19 illness and heart failure: a missing link? JACC Heart Fail. 8, 512–514 (2020).
Dewey, M. et al. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. Nat. Rev. Cardiol. 17, 427–450 (2020).
Manka, R. et al. Myocardial edema in COVID-19 on cardiac MRI. J. Heart Lung Transplant. 39, 730–732 (2020).
Fried, J. A. et al. The variety of cardiovascular presentations of COVID-19. Circulation 141, 1930–1936 (2020).
Liu, K. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin. Med. J. 133, 1025–1031 (2020).
Lakkireddy, D. R. et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 task force; electrophysiology section of the American College of Cardiology; and the electrocardiography and arrhythmias committee of the council on clinical cardiology, American Heart Association. Circulation 141, e823–e831 (2020).
Panigada, M. et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 18, 1738–1742 (2020).
Ranucci, M. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 18, 1747–1751 (2020).
Taylor, F. B. Jr. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86, 1327–1330 (2001).
Oxley, T. J. et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N. Engl. J. Med. 382, e60 (2020).
Bellosta, R. et al. Acute limb ischemia in patients with COVID-19 pneumonia. J. Vasc. Surg. https://doi.org/10.1016/j.jvs.2020.04.483 (2020).
Paranjpe, I. et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 76, 122–124 (2020).
Tang, N. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 18, 1094–1099 (2020).
Qiu, H. et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect. Dis. 20, 689–696 (2020).
Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395, 1771–1778 (2020).
Aslam, S. & Mehra, M. R. COVID-19: yet another coronavirus challenge in transplantation. J. Heart Lung Transplant. 39, 408–409 (2020).
Li, F., Cai, J. & Dong, N. First cases of COVID-19 in heart transplantation from China. J. Heart Lung Transplant. 39, 496–497 (2020).
Ketcham, S. W. et al. Coronavirus disease-2019 in heart transplant recipients in southeastern Michigan: a case series. J. Card. Fail. 26, 457-461(2020).
Latif, F. et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.2159 (2020).
Ganatra, S., Hammond, S. P. & Nohria, A. The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer. JACC CardioOncol. https://doi.org/10.1016/j.jaccao.2020.03.001 (2020).
Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020).
Turner, A. J., Hiscox, J. A. & Hooper, N. M. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol. Sci. 25, 291–294 (2004).
GTEx Portal (ACE2). Gene expression for ACE2 https://www.gtexportal.org/home/gene/ACE2 (2020).
Chen, L., Li, X., Chen, M., Feng, Y. & Xiong, C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc. Res. 116, 1097–1100 (2020).
Litvinukova, M. et al. Cells and gene expression programs in the adult human heart. Preprint at bioRxiv https://doi.org/10.1101/2020.04.03.024075 (2020).
Kaiser, J. How sick will the coronavirus make you? The answer may be in your genes. Science https://doi.org/10.1126/science.abb9192 (2020).
The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718 (2020).
Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116 (2005).
Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).
Crackower, M. A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828 (2002).
Thomas, M. C. et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107, 888–897 (2010).
Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Preprint at bioRxiv https://doi.org/10.1101/2020.01.26.919985 (2020).
Qi, F., Qian, S., Zhang, S. & Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 526, 135–140 (2020).
Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 26, 681–687 (2020).
Vaduganathan, M. et al. Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19. N. Engl. J. Med. 382, 1653–1659 (2020).
Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913 (2020).
Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783–792 (2013).
Khan, A. et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit. Care 21, 234 (2017).
Wadman, M., Couzin-Frankel, J., Kaiser, J. & Matacic, C. A rampage through the body. Science 368, 356–360 (2020).
Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2011400 (2020).
Kuster, G. M. et al. SARS-CoV-2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur. Heart J. 41, 1801–1803 (2020).
Sommerstein, R., Kochen, M. M., Messerli, F. H. & Grani, C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J. Am. Heart Assoc. 9, e016509 (2020).
Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605–2610 (2005).
Bozkurt, B., Kovacs, R. & Harrinton, B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. AHA Professional Heart Daily https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp (2020).
de Simone, G. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. ESC escardio https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (2020).
Chinese Society of Cardiology. Scientific statement on using renin–angiotensin system blockers in patients with cardiovascular disease and COVID-19. Chin. J. Cardiol. 48, E014 (2020).
de Abajo, F. J. et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet 395, 1705–1714 (2020).
Mancia, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin–angiotensin–aldosterone system blockers and the risk of COVID-19. N. Engl. J. Med. 382, 2431–2440 (2020).
Reynolds, H. R. et al. Renin–angiotensin–aldosterone system inhibitors and risk of COVID-19. N. Engl. J. Med. 382, 2441–2448 (2020).
Mehta, N. et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1855 (2020).
Ishiyama, Y. et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970–976 (2004).
Soler, M. J. et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am. J. Physiol. Ren. Physiol 296, F398–F405 (2009).
Burrell, L. M. et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 26, 369–375; discussion 322–324 (2005).
Ocaranza, M. P. et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48, 572–578 (2006).
Luque, M. et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J. Hypertens. 14, 799–805 (1996).
Furuhashi, M. et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am. J. Hypertens. 28, 15–21 (2015).
Epelman, S. et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J. Card. Fail. 15, 565–571 (2009).
Ramchand, J. et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc. Imaging 13, 655–664 (2020).
Walters, T. E. et al. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace 19, 1280–1287 (2017).
Ramchand, J., Patel, S. K., Srivastava, P. M., Farouque, O. & Burrell, L. M. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One 13, e0198144 (2018).
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).
Andersen, P. I. et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 93, 268–276 (2020).
Guy, R. K., DiPaola, R. S., Romanelli, F. & Dutch, R. E. Rapid repurposing of drugs for COVID-19. Science 368, 829–830 (2020).
Roden, D. M., Harrington, R. A., Poppas, A. & Russo, A. M. Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation 141, e906–e907 (2020).
Chen, Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Preprint at medRxiv https://doi.org/10.1101/2020.03.22.20040758 (2020).
Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 105949, https://doi.org/10.1016/j.ijantimicag.2020.105949 (2020).
Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G. & Cauda, R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect. Dis. 3, 722–727 (2003).
ISAC/Elsevier statement. Joint ISAC and Elsevier statement on Gautret et al. paper. International Society of Antimicrobial Chemotherapy https://www.isac.world/news-and-publications/isac-elsevier-statement (2020).
Yu, B. et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci. China Life. Sci. https://doi.org/10.1007/s11427-020-1732-2 (2020).
Geleris, J. et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N. Engl. J. Med. 382, 2411–2418 (2020).
Fihn, S. D., Perencevich, E. & Bradley, S. M. Caution needed on the use of chloroquine and hydroxychloroquine for coronavirus disease 2019. JAMA Netw. Open. 3, e209035 (2020).
Mercuro, N. J. et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1834 (2020).
Hancox, J. C., Hasnain, M., Vieweg, W. V., Crouse, E. L. & Baranchuk, A. Azithromycin, cardiovascular risks, QTc interval prolongation, Torsade de Pointes, and regulatory issues: a narrative review based on the study of case reports. Ther. Adv. Infect. Dis. 1, 155–165 (2013).
Rosenberg, E. S. et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA https://doi.org/10.1001/jama.2020.8630 (2020).
Grein, J. et al. Compassionate use of remdesivir for patients with severe COVID-19. N. Engl. J. Med. 382, 2327–2336 (2020).
Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).
Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).
Beigel, J. H. et al. Remdesivir for the treatment of COVID-19 – preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).
US FDA. Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™). https://www.fda.gov/media/137566/download (2020).
Cao, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787–1799 (2020).
Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).
Centers for Disease Control and Prevention. Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html (CDC, 2020).
World Health Organization. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). https://www.who.int/publications-detail/laboratory-biosafety-guidance-related-to-coronavirus-disease-2019-(covid-19) (2020).
Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature https://doi.org/10.1038/s41586-020-2312-y (2020).
Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).
Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016–1020 (2020).
McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
Kim, Y. I. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 27, 704–709 (2020).
Park, S. J. et al. Ferret animal model of severe fever with thrombocytopenia syndrome phlebovirus for human lethal infection and pathogenesis. Nat. Microbiol. 4, 438–446 (2019).
Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa325 (2020).
Bao, L. et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. Preprint at bioRxiv https://doi.org/10.1101/2020.03.13.990226 (2020).
Chen, I. Y., Matsa, E. & Wu, J. C. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat. Rev. Cardiol. 13, 333–349 (2016).
Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 16, 115–130 (2017).
Sharma, A. et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep. Med. https://doi.org/10.1016/j.xcrm.2020.100052 (2020).
McCauley, K. B., Hawkins, F. & Kotton, D. N. Derivation of epithelial-only airway organoids from human pluripotent stem cells. Curr. Protoc. Stem Cell Biol. 45, e51 (2018).